TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Tempus AI

Summary

The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * ≥18 years of age * Willing and able to provide informed consent * Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies * Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy * Must submit tumor tissue sample representative of current disease per laboratory manual Exclusion Criteria: * Non-squamous histologies (eg, nasopharynx or salivary gland) * Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy * Tumors that are PD-L1 negative (CPS \<1) * C…

Locations (32)

City of Hope
Duarte, California
ahamilton@coh.org 626-218-0109
USC/Norris Comprehensive Cancer Center
Los Angeles, California
sandy.tran@med.usc.edu
University of California, Los Angeles
Los Angeles, California
YZaki@mednet.ucla.edu 310-794-4955
Stanford
Palo Alto, California
savannab@stanford.edu 650-497-7418
Providence Medical Foundation
Santa Rosa, California
Davina.Montelongo@providence.org 707-521-3830
Mayo Clinic Florida
Jacksonville, Florida
Frisch.Jared@mayo.edu 904-953-8903